
==== Front
World J Methodol
WJM
World Journal of Methodology
2222-0682
Baishideng Publishing Group Inc

jWJM.v14.i3.eid92983
10.5662/wjm.v14.i3.92983
92983
Meta-Analysis
Anticoagulant use before COVID-19 diagnosis prevent COVID-19 associated acute venous thromboembolism or not: A systematic review and meta-analysis
Iqbal K et al. Pre-COVID-19 anticoagulation and VTE risk
Iqbal Kinza Department of Internal Medicine, Dow Medical College, Karachi 74200, Pakistan

Banga Akshat Department of Internal Medicine, Sawai Man Singh Medical College, Jaipur 302004, India

Arif Taha Bin Department of Internal Medicine, Dow Medical College, Karachi 74200, Pakistan

Rathore Sawai Singh Department of Internal Medicine, Dr. Sampurnanand Medical College, Jodhpur 342003, Rajasthan, India

Bhurwal Abhishek Department of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ 08901, United States

Naqvi Syeda Kisa Batool Department of Internal Medicine, Dow Medical College, Karachi 74200, Pakistan

Mehdi Muhammad Department of Internal Medicine, Dow Medical College, Karachi 74200, Pakistan

Kumar Pankaj Department of Internal Medicine, Dow Medical College, Karachi 74200, Pakistan

Salklan Mitali Madhu Department of Internal Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak 124001, Haryana, India

Iqbal Ayman Department of Internal Medicine, Dow Medical College, Karachi 74200, Pakistan

Ahmed Jawad Department of Internal Medicine, Dow Medical College, Karachi 74200, Pakistan

Sharma Nikhil Department of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, United States

Lal Amos Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, United States

Kashyap Rahul Department of Research, Wellspan Health, York, PA 17403, United States

Bansal Vikas Department of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, United States. bansal.vikas@mayo.edu

Domecq Juan Pablo Department of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, United States

Co-first authors: Kinza Iqbal and Akshat Banga.

Co-corresponding authors: Vikas Bansal and Juan Pablo Domecq.

Author contributions: Iqbal K and Bansal V contributed equally to defining the study outline and manuscript writing; Data review and collection were done by Banga A, Iqbal A, Ahmed J, Iqbal K, Sharma N, Mehdi M, Kumar P, and Rathore SS; Statistical analysis was done by Banga A, Iqbal K, and Bansal V; Study design and critical review are done by Banga A, Lal A, Domecq JP, Kashyap R, and Bansal V; Iqbal K and Bansal V are the co-corresponding authors of the paper, taking responsibility for the integrity of the work from inception to the published article; all authors contributed to the article and approved the submitted version. Bansal V and Domecq JP contributed equally to this work and are considered co- corresponding authors.

Corresponding author: Vikas Bansal, MBBS, Associate Research Scientist, Department of Nephrology and Hypertension, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, Rochester, MN 55905, United States. bansal.vikas@mayo.edu

20 9 2024
20 9 2024
14 3 9298315 2 2024
24 4 2024
11 5 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
BACKGROUND

Coagulopathy and thromboembolic events are associated with poor outcomes in coronavirus disease 2019 (COVID-19) patients. There is conflicting evidence on the effects of chronic anticoagulation on mortality and severity of COVID-19 disease.

AIM

To summarize the body of evidence on the effects of pre-hospital anticoagulation on outcomes in COVID-19 patients.

METHODS

A Literature search was performed on LitCovid PubMed, WHO, and Scopus databases from inception (December 2019) till June 2023 for original studies reporting an association between prior use of anticoagulants and patient outcomes in adults with COVID-19. The primary outcome was the risk of thromboembolic events in COVID-19 patients taking anticoagulants. Secondary outcomes included COVID-19 disease severity, in terms of intensive care unit admission or invasive mechanical ventilation/intubation requirement in patients hospitalized with COVID-19 infection, and mortality. The random effects models were used to calculate crude and adjusted odds ratios (aORs) with 95% confidence intervals (95%CIs).

RESULTS

Forty-six observational studies met our inclusion criteria. The unadjusted analysis found no association between prior anticoagulation and thromboembolic event risk [n = 43851, 9 studies, odds ratio (OR)= 0.67 (0.22, 2.07); P = 0.49; I2 = 95%]. The association between prior anticoagulation and disease severity was non-significant [n = 186782; 22 studies, OR = 1.08 (0.78, 1.49); P = 0.64; I2 = 89%]. However, pre-hospital anticoagulation significantly increased all-cause mortality risk [n = 207292; 35 studies, OR = 1.72 (1.37, 2.17); P < 0.00001; I2 = 93%]. Pooling adjusted estimates revealed a statistically non-significant association between pre-hospital anticoagulation and thromboembolic event risk [aOR = 0.87 (0.42, 1.80); P = 0.71], mortality [aOR = 0.94 (0.84, 1.05); P = 0.31], and disease severity [aOR = 0.96 (0.72, 1.26); P = 0.76].

CONCLUSION

Prehospital anticoagulation was not significantly associated with reduced risk of thromboembolic events, improved survival, and lower disease severity in COVID-19 patients.

Prior anticoagulation
COVID-19
Prehospital anticoagulation
Chronic anticoagulation
Mortality
Severity
Thromboembolic events
==== Body
pmc Core Tip: Coronavirus disease 2019 (COVID-19) patients are at an increased risk of developing thromboembolic events and hypercoagulable disorders, which are poor prognostic indicators of COVID-19 disease. The results of different observational studies on the effects of chronic anticoagulation on the mortality and severity of COVID-19 disease in infected patients are inconsistent. This systematic review and meta-analysis provide a comprehensive assessment of the risk of thromboembolic events, mortality, and severity of COVID-19 disease in patients on prehospital anticoagulation treatment.

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 and was later termed coronavirus disease 2019 (COVID-19)[1]. While Acute Respiratory Distress Syndrome (ARDS) was the predominant complication associated with a potentially fatal outcome, the infection progression could also be influenced by other risk factors like diabetes, coronary artery disease, chronic kidney disease, metabolic syndrome, psychiatric and neurological complications[2-12]. Due to the complexity of these complications, a standardized treatment approach for COVID-19 has yet to be universally agreed upon to guide healthcare professionals worldwide[10,13-15].

Studies have described that multi-organ involvement in COVID-19 is associated with endothelial dysfunction and thrombosis[16]. Moreover, COVID-19 has been observed to influence clotting system pathways and activate platelets, potentially resulting in vascular inflammation, hypercoagulability, and endothelial dysfunction[17]. As a result, thromboembolic events are found to be a common complication in these individuals, with an incidence rate of around 25% for Venous Thromboembolism (VTE)[16]. SARS-CoV-2-related coagulopathy is distinct from other causes of coagulopathy that result in VTE as it involves a significant element of inducing systemic inflammation and endothelitis, which might not be effectively addressed by conventional anticoagulant treatment methods[18]. Regardless, emerging research evidence suggests that anticoagulation therapy has shown effectiveness in COVID-19 patients, particularly in noncritically ill hospitalized cases[19].

Studies mostly emphasize using anticoagulation therapy during hospitalization; however, the relationship between pre-existing chronic anticoagulation due to non-COVID-19 indication and clinical outcomes in COVID-19-infected patients remains largely unknown. This meta-analysis aims to analyze the relationship between VTE risk in COVID-19 disease and prehospital anticoagulation and to study the impact of prehospital anticoagulation on COVID-19 disease severity and mortality.

MATERIALS AND METHODS

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed in this systematic review and meta-analysis[20]. The protocol for this meta-analysis was registered on PROSPERO (CRD42022306893).

Data sources and literature search strategy

Two independent investigators (Iqbal K and Rathore SS) utilized databases, including LitCovid, WHO, and Scopus, to conduct a systemic literature search for relevant articles from December 2019 to June 30, 2023 (Supplementary Table 1). A combination of keywords, such as “anticoagulant”, “direct oral anticoagulants”, “DOAC”, “vitamin K antagonist”, “VKA”, “dabigatran”, “rivaroxaban”, “apixaban”, “edoxaban”, “warfarin”, “heparin”, “prehospital”, “prehospital”, “preadmission”, “pre-admission”, “chronic”, “long-term”, “pre-hospital”, and “prior”, were searched electronically[21].

Study selection and inclusion criteria

Duplicates within the articles retrieved from our systemic search were identified and eliminated using Endnote (Clarivate Analytics, Thomson Reuters Corporation, Philadelphia, Pennsylvania). Two independent researchers (Iqbal K and Rathore SS) screened the articles based on their titles, abstracts, and keywords. The articles were subsequently assessed for relevance through full-text screening. Data review and collection were done by Bhurwal A, Iqbal A, Ahmed J, Iqbal K, Sharma N, Mehdi M, Kumar P, and Rathore SS. References to the shortlisted articles were also screened for additional studies. Any disagreement was resolved by discussing within the group or through an independent reviewer’s (Bansal V) inputs. Articles that failed to fulfill the inclusion criteria were removed. For the meta-analysis, the inclusion criteria were: (1) All retrospective or prospective observational studies enrolling patients ≥ 18 years; (2) Studies that compared outcomes of COVID-19-infected patients who had been on anticoagulation before their COVID-19 diagnosis for any indication vs those that did not receive any prehospital anticoagulation; and (3) Studies including data (raw or adjusted) for at least one of the outcomes of interest. Exclusion criteria consisted of: (1) Studies without a control group; (2) Studies with no outcome of interest (new incidence of thromboembolic events, all-cause mortality, severity of COVID-19 (defined as per WHO Ordinal scale 6-9); and (3) Literature reviews or narrative reviews or case reports.

Our primary outcome of interest was the incidence of VTE in COVID-19-infected adults on chronic anticoagulation prior to the infection. Mortality and disease severity were considered secondary outcomes. COVID-19 disease severity was based on the WHO ordinal scale[22]. A WHO clinical progression scale score of 6-9 indicated severe COVID-19, often necessitating intensive care unit (ICU) admission. In cases where this scale was not used, the highest WHO ordinal scale event was used as a substitute for severe infection. If ICU admission rates were unavailable, intubation or non-invasive mechanical ventilation rates were considered to assess COVID-19 severity. The cases included SARS-CoV-2 positive hospitalized patients with prehospital use of anticoagulants. The controls were COVID-19-positive hospitalized patients with no history of prehospital anticoagulation. Both raw data and their adjusted estimates were derived for the meta-analysis. Estimates from studies that performed propensity-matched scoring were also considered as adjusted estimates.

Statistical analysis

We used Review Manager v.5.4 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2014)[23] for unadjusted and adjusted analysis and Comprehensive Meta-Analysis software package 154 (Biostat, Englewood, NJ, United States)[24] for the meta-regression analysis. For the unadjusted analysis, we calculated the Mantel Haenszel crude odds ratios (ORs) using a random-effects model with a 95% confidence interval (95%CI). We also calculated the adjusted OR (aOR) with 95%CI to measure adjusted estimates. Adjusted estimates were used for the primary analysis to produce more reliable results as it considers the baseline differences between the two groups (prior anticoagulant users and non-users) that may influence the outcomes. In all cases, significance was defined by a P-value < 0.05, and all analyses utilized a random-effects model. Statistical heterogeneity was gauged among the included articles using the Higgins I2 statistics, and I2 > 50% was regarded as substantial heterogeneity. To reduce the inherent selection bias in observational studies, a subgroup analysis based on study design was performed[25].

We conducted univariate and multivariate meta-regression analyses with random effects (maximum likelihood approach) to examine potential study variations that could impact the effect magnitude. The age and gender distribution of the study sample, the study's country of origin, and the percentage of participants with comorbid conditions like obesity, diabetes, pulmonary illness, dyslipidemia, cardiovascular disease, and hypertension were all considered potential sources of variability. If covariates significantly (P < 0.05) altered the relationship between mortality or severity in COVID-19 hospitalized patients and prehospital anticoagulant usage, they were chosen for additional modeling. Two models were developed: one for mortality and the other for the severity of the condition. Then, using P = 0.05 as the cutoff threshold for elimination, preselected factors were included in a manual backward and stepwise multiple meta-regression analysis. P < 0.05 (P < 0.10 for heterogeneity) was used to define statistical significance. The meta-analysis and meta-regression tests were all two-tailed.

Risk of Bias and Quality assessment

Two investigators (Kumar P, Iqbal A) assessed the included studies’ methodological quality through the Newcastle-Ottawa Scale (Supplementary Table 2)[26]. The following categories were used to evaluate every study: (1) Study group selection; (2) Study group comparability; and (3) Determination of the desired outcomes (Supplementary Table 2). The publishing bias likelihood was tested using Egger regression methods, and the results were visually examined using funnel plots (Supplementary Figure 1). The degree of evidence certainty at the outcome level was evaluated using the GRADE pro profiler (GRADE working group, McMaster University, and Evidence Prime Inc; Supplementary Table 3)[27].

RESULTS

The initial database search produced 2056 articles of potential relevance. After eliminating the duplicates, 956 articles were filtered for appropriateness and relevancy using their titles, abstracts, and keywords. Of them, 86 full-text papers relevant to the manuscript's objectives were examined. The final analysis included 46 studies comprising 41 cohort studies (36 retrospective, 2 ambispective, and 3 prospective), three case-control studies, and one cross-sectional study. The PRISMA flowchart outlining the search process is shown in Figure 1. Table 1 provides an overview of the study characteristics of the included publications, and Table 2 shows the studies reporting adjusted estimates along with the covariates for which the estimates are adjusted.

Figure 1 PRISMA flow diagram.

Table 1 Study characteristic table for included studies

Ref.	Country of study	Study design	Setting	Total COVID-19 positive patients	Total patients with pre-admission anticoagulation	Type of anticoagulant	Duration of anticoagulant	Indication for anticoagulant Use	Definition Of Severity	Mean age ± SD (yr)	Female sex proportion (%)	Diabetes proportion (%)	Hypertension proportion (%)	Pulmonary disease proportion (%)	Arrhythmia proportion (%)	
Ageno et al[28], 2021	Italy	Retrospective observational study	Inpatient hospitalized	4396	43	DOAC or VKA	-	AF	NA	-	-	-	-	-	56.4	
Arachchillage et al[29], 2022	United Kingdom	Ambispective cohort study	Inpatient hospitalized	5883	963	DOAC (rivaroxaban, apixaban, edoxaban, dabigatran, or VKA (warfarin)	-	VTE or heart disease or AF	ICU admission	-	44.81	28.96	47.12	24.55	-	
Aslan et al[55], 2021	Turkey	Retrospective cohort study	Inpatient hospitalized	1710	79	DOAC (dabigatran, rivaroxaban, apixaban, edoxaban)	-	AF, venous thrombosis	ICU admission	62
(52-71)	50.5	27	42	6	5	
Bauer et al[71], 2021	United States	Case–control study	Hospitalized and non-hospitalized patients	1449	-	-		-	Admitted to the hospital/died	54.7 ± 22.5	63	17	36	22	-	
Boari et al[68], 2020	Italy	Retrospective cohort study	Inpatient hospitalized	258	29	-	-	-	NA	71.0 ± 13.8	32.9	26	58.5	14	-	
Brouns et al[53], 2020	Netherlands	Retrospective case-series	Inpatient hospitalized	101	18	DOAC or VKA	-	-	-	-	-	-	-	-	-	
Buenen et al[40], 2021	Netherlands	Cohort study	Hospitalized and non-hospitalized patients	497	110	DOAC or VKA	-	-	NA	-	36.2	20.5	52.1	26	-	
Chocron et al[41], 2021	France	Retrospective cohort study	Inpatient hospitalized	2878	382	DOAC or VKA	-	AF, VTE	ICU admission	-	40.3	30.3	75.3	-	24.8	
Corrochano et al[30], 2022	Spain	Retrospective observational study	Inpatient hospitalized	1598	155	VKA (warfarin or acenocoumarol), DOAC (dabigatran, rivaroxaban, apixaban or edoxaban), or heparins	-	-	ICU admission	66.5 (17.1)	47.1	20	50.8	-	-	
Covino et al[42], 2021	Italy	Retrospective observational study	Emergency department	184	92	DOAC or VKA	1 month	AF	NA	84
(81-87)	50	18.5	41.8	17.4	-	
Denas et al[43], 2021	Italy	Retrospective observational study	Hospitalized and non-hospitalized patients	4697	651	VKA, NOAC (dabigatran, rivaroxaban, apixaban) or edoxaban	6 months	AF	ICU admission	-	45.6	24.1	87.3	-	-	
Fauvel et al[54], 2020	France	Retrospective observational study	Inpatient hospitalized	1240	136	VKA 47 (3.8), NOAC 78 (6.3), heparin 11 (0.9)	-	-	ICU admission and mechanical ventilation	-	-	-	-	-	-	
Flam et al[59], 2021	Sweden	Prospective cohort study	Inpatient hospitalized	459402	103703	DOAC (dabigatran, apixaban, rivaroxaban or edoxaban)	0–6 months [7394 (7.1%)]; 7–24 months [29012 (28.0%)]; > 24 months [67245 (64.8%)]	AF and atrial flutter	Hospital admission and ICU admission	-	-	-	-	-	-	
Fröhlich et al[31], 2021	Germany	Retrospective cohort study	Inpatient hospitalized	6637	731	DOAC or VKA	6 months	AF	NA	-	50	25	93	-	76	
Fumagalli et al[44], 2022	Italy	Retrospective cohort study	Inpatient hospitalized	176	91	DOAC or VKA	-	AF	NA	-	48.3	33	71	21	11.9	
Gülcü et al[32], 2022	Turkey	Retrospective cohort study	Inpatient hospitalized	5575	451	DOAC (rivaroxaban, apixaban, edoxaban, dabigatran), and VKA (warfarin)	-	-	NA	64
(51–74)	49.8	26.9	49.5	13.9	5.2	
Hanif et al[33], 2020	United States	Retrospective cohort study	Inpatient hospitalized	58	33	DOAC (rivaroxaban, apixaban, edoxaban, and dabigatran), VKA (warfarin)	-	-	NA	-	34.5	-	-	-	-	
Harrison et al[34], 2021	United States	Retrospective cohort study	Inpatient hospitalized	1027	132	DOAC (rivaroxaban, apixaban, dabigatran), and VKA (warfarin)	-	-	NA	-	52.5	38.7	74.3	-	21.1	
Ho et al[45], 2021	United States	Retrospective cohort study	Hospitalized and non-hospitalized patients	28076	304	VKA (warfarin) or DOAC (dabigatran)	Within 3 months prior to SARS-Cov-2 diagnosis	-	ICU admission	-	51.6	8.3	7.2	-	-	
Hozayen et al[35], 2021	United States	Prospective cohort study	Outpatient and inpatient	5597	160	Enoxaparin, VKA (warfarin), DOAC	Within 3 months prior to SARS-Cov-2 diagnosis	-	NA	51 ± 22	57.1	15.7	34.7	4.5	12	
Iaccarino et al[72], 2021	Italy	Cross-sectional study	Inpatient hospitalized	2377	125	DOAC	6 months	AF, mechanic valvularreplacement, pulmonary thromboembolism prophylaxis	ICU admission	68.2 ± 0.38	37.3	18	59	-	4.7	
Klok et al[61], 2020	Denmark	Retrospective cohort study	Intensive care	184	17	-	-	-	NA	-	-	-	-	-	-	
Li et al[36], 2020	China	Ambispective cohort study	Inpatient hospitalized	547	16	-	-	-	Severe COVID-19 infection	60
(48-69)	49.1	15.1	30.3	3.1	-	
Lodigiani et al[73], 2020	Italy	Retrospective cohort study	Inpatient hospitalized	388	33	DOAC or VKA	-	-	ICU admission	66
(55–75)	32	22.7	47.2	9	-	
Ménager et al[60], 2020	France	Retrospective cohort study	Inpatient hospitalized	82	9	VKA (warfarin or acenocoumarol or fluindione)	-	-	NA	88 (85–92)	47.6	23.2	63.4	-	36.6	
Middeldorp et al[62], 2020	Netherlands	Retrospective cohort study	Inpatient hospitalized	198	19	-	-	AF	ICU admission	61± 14	34	-	-	-	-	
Natali et al[63], 2020	United States	Retrospective case control study	Inpatient hospitalized	400	22	-	-	-	NA	-	-	-	-	--	-	
Olcott et al[46], 2021	England.	Retrospective cohort study	Inpatient hospitalized	309	81	DOAC or VKA	-	-	NA	-	47.9	-	-	-	-	
Parker et al[47], 2021	United Kingdom	Retrospective cohort study	Inpatient hospitalized	1032	164	DOAC, VKA, LMWH, fondaparinux	Taking the anticoagulant for > 1 month	AF, VTE, metallic heart valve, LV thrombus	ICU admission	71
(56–83)	44.9	29.3	44.3	-	-	
Philipose et al[66], 2020	United Kingdom	Retrospective cohort study	Inpatient hospitalized	466	68	-	-	-	NA	-	-	-	50.2	28.1	-	
Reilev et al[64], 2020	Denmark	Cohort study	Community-managed and hospitalized	11122	577	-	At least one filled prescription within 6 months prior to the test date	-	ICU admission	48
(33–62)	62	6.4	24	12	4.6	
Rieder et al[37], 2022	Multi-Country	Retrospective cohort study	Hospitalized and outpatient	1433	334	VKA or non-VKA DOAC (rivaroxaban, apixaban, edoxaban, dabigatran etexilate)	-	AF	NA	-	39.8	31.2	86.5	-	25.4	
Rivera-Caravaca et al[58], 2021	International, HOPE COVID-19 Registry	Retrospective cohort study	Inpatient hospitalized	1002	110	DOAC or VKA	-	AF, VTE, mechanical heart valves	NA	-	40.8	31.2	82.1	18.3	-	
Rivera-Caravaca et al[38], 2021	United States, Trinetx	Cohort study	Hospitalized and outpatient	26006	13003	DOAC (dabigatran, apixaban, rivaroxaban or edoxaban)	1 yr	-	NA	-	48.4	37.9	71.9	18.3	48.1	
Rodríguez-Molinero et al[67], 2020	Spain	Retrospective cohort study	Inpatient hospitalized	418	34	-	-	-	Need for oxygen therapy through a nonrebreather mask or mechanical ventilation	65.4 ± 16.6	43.1	23.7	52	9.8	10.8	
Rossi et al[57], 2020	Italy	Retrospective observational study	Outpatient	70	26	DOAC (eivaroxaban, apixaban, edoxaban, dabigatran)	Regularly taken by the patient for at least 6 months	AF, pulmonary embolism, or DVT	NA	-	50	25.7	61.4	15.7	-	
Russo et al[48], 2022	Italy	Retrospective observational study	Inpatient hospitalized	467	87	DOAC (edoxaban, dabigatran, rivaroxaban, apixaban), VKA (warafrin)	-	AF, prosthetic heart valve, venous thromboembolism	NA	-	33.3	25.3	74	18.8	-	
Ruzhentsova et al[56], 2021	Italy	Retrospective cohort study	Outpatient	76	26	DOAC (rivaroxaban, apixaban, dabigatran)	-	-	NA	-	56.6	26.3	77.6	-	36.8	
Schiavone et al[74], 2021	Italy	Retrospective cohort study	Inpatient hospitalized	844	65	DOAC or VKA	-	-	ICU admission	63.4 ± 16.1	38.3	16.6	45.1	7.4	9.2	
Sivaloganathan et al[49], 2020	United Kingdom	Case-control study	Inpatient hospitalized	180	31	VKA (warfarin), DOAC (dabigatran, rivaroxaban, apixaban), or LMWH	-	-	ICU admission	-	-	-	-	-	-	
Spiegelenberg et al[50], 2021	Netherlands	Retrospective cohort study	Inpatient hospitalized	1154	190	DOAC or VKA	-	AF, VTE, mechanical valve replacement, cardiac arrest in history, or unknown (5%)	ICU admission	-	32.2	27.3	53.8	26.1	-	
Tehrani et al[69], 2021	Sweden	Retrospective cohort study	Inpatient hospitalized	255	49	-	-	-	NA	66 ± 17	41	31	54	13	-	
Togano et al[39], 2021	Japan	Retrospective cohort study	Inpatient hospitalized	4026	105	VKA (warfarin), DOAC (dabigatran, rivaroxaban, apixaban, or edoxaban)	-	-	Mechanical ventilation/ supplemental oxygen/SPO2 ≤94% on room air/tachypnea	52.0
(34–69)	40.1	14.1	19	8.1	-	
Tremblay et al[70], 2020	United States	Retrospective cohort study	Hospitalized and ambulatory patients	3772	241	-	-	-	Intubation-mechanical ventilation	56.6 (18.2)	45.2	-	-	14.9	-	
van Haaps et al[51], 2021	Denmark	Retrospective cohort study	Inpatient hospitalized	3006	445	DOAC, VKA, LMWH	-	-	ICU admission	-	35.1	37.8	59.5	8.3	-	
Wargny et al[65], 2021	France	Retrospective cohort study	Inpatient hospitalized	2796	501	-	-	-	NA	69.7 ± 13.2	36.3	100	76.8	9.6	-	
Defined according to the 2019 clinical practice guideline from the Infectious Diseases Society of America and the American Thoracic Society for diagnosis and treatment of adults with community acquired pneumonia. DOAC: Direct-acting oral anticoagulants; VKA: Vitamin K antagonists; ARDS: Acute respiratory distress syndrome; NOAC: Non-Vitamin K oral anticoagulants; AF: Atrial fibrillation; VTE: Venous thromboembolism; DVT: Deep venous thrombosis; CAD: Coronary artery disease; NA: Not applicable; IQR: Interquartile range; OAC: Oral anticoagulant.

Table 2 Studies reporting adjusted estimates and the factors for which they are adjusted

Ref.	Outcome	Adjusted estimates	
Ageno et al[28], 2021	Mortality	Age, gender, and heparin use after admission, history of acute MI, T2D, HTN, cancer, COPD, renal function and CRP at hospital entry	
Arachchillage et al[29], 2022	90-day mortality, thrombosis, and ICU admission	Age, gender, BMI, antiplatelet treatment prior to admission, autoimmune disease, malignancy, hypercholesterolaemia, heart disease, T2D, smoking status, liver disease, lung disease, existing renal failure and whether renal failure was dialysis dependent	
Aslan et al[55], 2021	In-hospital mortality	Age, male gender, T2D, ferritin, d-dimer, neutrophil, lymphocyte, creatinine, CRP, SaO2, procalcitonin, DOAC, HTN, HF, AF, CAD, COPD, systolic blood pressure and hematocrit in univariable logistic regression analysis	
Buenen et al[40], 2021	All-cause mortality within 30 d	Age, sex, symptom duration, home medication, and comorbidities	
Covino et al[42], 2021	All-cause in-hospital death.	Age, sex, comorbidity (categorized as CCI < 3 or CCI ≥ 3), and illness severity at admission (categorized as NEWS < 6 or NEWS ≥ 6)	
Gülcü et al[32], 2022	In-hospital all-cause mortality	Age, gender, HTN, DM, HF, CAD, eGFR, albumin, CRP, D-dimer, hemoglobin, platelet count, LDH, and oxygen saturation variables	
Bauer et al[71], 2020	Severity	Age and gender	
Ménager et al[60], 2020	7-day mortality	Age, sex, severe undernutrition, T2D, HTN, prior MI, HF, prior stroke and/or TIA, CHA2DS2-VASc score, HAS-BLED score, and eGFR	
Philipose et al[66], 2020	Mortality	Age and gender	
Rieder et al[37], 2022	COVID-19 related mortality	Age, gender, BMI and smoking status, the phase of disease at diagnosis, solid tumor, AF, CAD, prior MI, peripheral artery disease, HTN, cerebrovascular disease, and T2D	
Rivera-Caravaca et al[38], 2021	Mortality and the composite of any thrombotic or thromboembolic event	Age, gender and ethnicity, all the included comorbidities	
Rodríguez-Molinero et al[67], 2020	Mortality	Age, sex, obesity, and corticosteroids	
Russo et al[48], 2022	Mortality	Age, arterial HTN, T2D, CAD, HF, previous stroke	
Schiavone et al[74], 2021	Mortality	Age > 65 years, male gender, CAD, CKD, COPD, HF, OAC, PaO2/FiO2, hydroxychloroquine, tocilizumab, antivirals, heparin	
Spiegelenberg et al[50], 2021	All-cause in hospital mortality and ICU admission	Age, sex, body mass index, active malignancy, COPD, T2D, HTN, CAD, MI, HF, non-ischaemic cardiomyopathy, previous heart surgery, electronic heart device, cerebrovascular accident, peripheral artery disease, immunosuppressive medication, no ICU policy	
Togano et al[39], 2021	Severity (mechanical ventilation/ supplemental oxygen/SpO2 ≤ 94% on room air/tachypnea)	Age, gender, BMI, smoking, alcohol consumption, myocardial infarction/congestive heart failure, peripheral artery disease, cerebrovascular disease, dementia, paralysis, COPD, liver dysfunction, hypertension, hyperlipidemia, diabetes, obesity, leukemia, lymphoma, immunosuppression	
Tremblay et al[70], 2020	All-cause mortality, mechanical ventilation	Age, gender, race, CCI and obesity	
van Haaps et al[51], 2021	21-day all-cause mortality and ICU admission	Age, gender, T2D, HTN, CKD, asthma, obesity, time in pandemic, center, chronic cardiac disease, malignancy, liver disease, dementia, organ transplant, autoimmune disorder, and rheumatic disorder	
Wargny et al[65], 2021	Death within 28 d	Age	
Harrison et al[34], 2021	21-day all-cause in hospital mortality	Age, gender, and confounding variables	
Iaccarino et al[72], 2021	Mortality, ICU admission	Age, multimorbidity (combined in the CCI score), and gender	
Hozayen et al[35], 2021	Mortality	Age, sex, self-identified race/ethnicity (as a proxy for social, not biological risk factors), Elixhauser comorbidity score, and the presence/absence of any cardiovascular, immunological or hematological comorbidities	
Ho et al[45], 2021	ICU admission, VTE, and mortality between date of SARS-CoV-2 diagnosis and 45 d after diagnosis	Age, sex, race/ethnicity, body mass index, CCI, HTN, T2D, and smoking history as well as the week of SARS-CoV-2 diagnosis	
Denas et al[43], 2021	ICU admission and all-cause mortality	Age, sex, HF, HTN, cancer, T2D, history of stroke/TIA, previous bleeding, history of MI, peripheral artery disease, abnormal renal function, abnormal hepatic function, use of antiplatelet drugs, NSAIDs and statin use	
Corrochano et al[30], 2022	All-cause mortality and ICU admission	Sex, age, CCI, and antithrombotic therapy	
Chocron et al[41], 2021	In-hospital mortality and ICU admission	Sex, age, cardiovascular comorbidities (history of HTN, dyslipidemia, BMI, T2D, and current smoking), plasma creatinine level (µmol/L), CRP (mg/L), fraction of inspired oxygen, the degree of pulmonary lesions with ground-glass opacities and areas of consolidation, and the use of in-hospital anticoagulation (preventive low or high dose and therapeutic dose)	
T2D: Type 2 diabetes mellitus; HTN: Hypertension; HF: Heart failure; CAD: Coronary artery disease; MI: Myocardial infarction; AF: Atrial fibrillation; TIA: Transient ischemic attack; CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; VTE: Venous thromboembolism; OAC: Oral anticoagulant; DOAC: Direct oral anticoagulant; CRP: C-reactive protein; LDH: Lactate dehydrogenase; BMI: Body mass index; CCI: Charlson comorbidity index; NEWS: National Early Warning Score; ICU: Intensive care unit; NSAIDs: Non-steroidal anti-inflammatory drugs; eGFR: Estimated glomerular filtration rate; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19: Coronavirus disease 2019.

Out of the 46 studies included in our meta-analysis, 26 studies[28-54] described using both direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs). Five studies[55-59] had only DOAC as the prehospital anticoagulant, while a single study by Ménager et al[60] included patients only on VKAs. The anticoagulant type was unspecified in the remaining 13 studies[36,61-72]. In the 32 studies[28-35,37,39-51,53-60,73,74] studying DOACs Apixaban, Dabigatran, Edoxaban, and Rivaroxaban were the most commonly used, while on the other hand, VKAs were represented mostly by Warfarin. However, in two studies[30,60], Acenocoumarin was also taken into consideration. Supplemental prehospital use of other anticoagulants, including LMWH, Fondaparinux, and Enoxaparin, was observed in five studies[30,35,47,49,51].

Quality assessment and publication bias

The included studies’ methodological quality assessment demonstrated that 21 studies[25,28,30,34,36,38,39,43,44,50,54,56,58-60,63,66,68,69,71,72,73] had a high quality with very low risk of bias, while 24 studies[29,31-33,35,37,40-42,46-49,51,55,57,62,64,65,67,70,73,74] were of moderate quality (Supplementary Table 2). Out of the 24 studies with moderate quality, 11 studies[29,33,35,37,41,46-49,52,62] had an unclear risk of bias (not enough information to make a clear judgment), and the remaining 13 studies[31,32,40,46,55,57,64,65,67,70,73,74] had a low risk of bias, but some other potential flaws. Therefore, every study was approved for inclusion in the quantitative analysis. A single study was of poor quality and potentially high risk of bias[53]. Supplementary Figure 1 displays the publishing bias funnel plots. The results showed no discernible publication bias, and Supplementary Figure 1 displays the various P-values from Egger's regression test. We also evaluated the certainty of evidence at the outcome level using GRADE pro profiler (GRADE working group, McMaster University, and Evidence Prime Inc; Supplementary Table 3)[20].

Primary outcome

Thromboembolic event rate: A total of nine studies[29,30,37,40,45,50,54,60,70] evaluated the unadjusted risk, while six studies[29,45,50,54,58,61]calculated the adjusted risk between prehospital anticoagulation and new thromboembolic events in COVID-19 infected patients. Three studies[45,50,62] defined thromboembolic events as VTE, while three others[29,30,37] included both arterial and venous thromboembolic events, and the remaining three[40,70] did not clarify their definition of thromboembolic events.

Overall, anticoagulation prior to COVID-19 diagnosis suggested a reduction in the unadjusted risk of new VTE in adult patients in these nine studies but did not attain statistical significance [n = 43851, OR = 0.67 (0.22, 2.07); P = 0.49; I2 = 95%; Figure 2A]. Similarly, in the predefined subgroup analysis, the use of VKA[40,50,54] [2658 participants, OR = 0.32 (0.05, 1.98); P = 0.22; I2 = 63%; Supplementary Figure 2A] or DOAC[40,50,54] [2699 participants, OR = 0.36 (0.10, 1.25); P = 0.11; I2 = 51%; Supplementary Figure 2B] or any anticoagulants [40960 participants, OR = 1.03 (0.26, 4.08); P = 0.97; I2 = 96%; Supplementary Figure 2C] did not show a statistical significant reduction of new VTE event risk associated with COVID-19 infection (P value for subgroup differences = 0.70, I2 = 0%). Our prespecified adjusted meta-analysis on six studies[29,45,50,54,61,74] did not achieve statistical significance in the lower odds of thromboembolic events in patients suffering from COVID-19 [aOR = 0.87 (0.42, 1.80); P = 0.71; I2 = 99%; Figure 3A].

Figure 2 Unadjusted meta-analysis for mortality, severity thromboembolic events in prehospital use of anticoagulants vs control cohort in COVID-19. A: Unadjusted thromboembolic events in prehospital use of anticoagulants vs control cohort; B: Unadjusted mortality in prehospital use of anticoagulants vs control cohort; C: Unadjusted severity in prehospital use of anticoagulants vs control cohort.

Figure 3 Adjusted meta-analysis for mortality, severity thromboembolic events in prehospital use of anticoagulants vs control cohort in COVID-19. A: Adjusted thromboembolic events in prehospital use of anticoagulants vs control cohort; B: Adjusted mortality in prehospital use of Anticoagulants vs control cohort; C: Adjusted severity in prehospital use of Anticoagulants vs control cohort.

Secondary outcomes

Mortality: A total of 35[28-35,37,38,40,41,43,44,46-48,50,51,53,55-57,59,60,63-70,72,74] studies reported mortality in prior anticoagulant users (2388 deaths out of 110975 patients; 2.1%) vs non-users (9457 deaths out of 96317 patients; 9.8%). Prior anticoagulation was found to significantly increase the risk of mortality in COVID-19 patients in the unadjusted analysis [OR = 1.72 (1.37, 2.17); P < 0.00001; I2 = 93%; Figure 2B). Subgroup analysis by the type of anticoagulation medication showed that prior VKA use [19747 participants, OR = 1.91 (1.20, 3.06); P = 0.007; I2 = 83%; Supplementary Figure 3A] and any anticoagulant use [43643 participants, OR = 1.88 (1.40, 2.52); P < 0.00001; I2 = 94%; Supplementary Figure 3B] was associated with an increased mortality risk. However, prior use of DOAC [22374 participants, OR = 1.42 (0.95, 2.12); P = 0.08; I2 = 87%; Supplementary Figure 3C] and the adjusted estimates of 28 studies[28,30,32,34,35,37,38,40-45,48,50,51,53,55,57,60,61,65-67,70,72,74] [aOR = 0.94 (0.84, 1.05); P = 0.31; I2 = 65%; Figure 3B] revealed no statistically significant association between prehospital anticoagulation and mortality in patients hospitalized for COVID-19.

COVID-19 disease severity: Overall, 22 studies[30,31,33,36,39,41,43,47-51,55,56,59,62,64,67,70,72,73,74] documented the association between prehospital anticoagulation and COVID-19 infection severity. ICU admission was the surrogate marker of COVID-19 severity in 15 studies, while mechanical ventilation was used in five studies, and one study used ARDS development during hospitalization. Six hundred seventy-one patients out of 103,703 who received anticoagulants before COVID-19 diagnosis developed severe COVID-19 infection, while 6155 out of 78890 non-users progressed to severe COVID-19 illness. We derived no statistically significant association between prehospital anticoagulation and COVID-19 disease severity [OR = 1.08 (0.78, 1.49); P = 0.64; I2 = 89%; Figure 2C]. On carrying out a subgroup analysis based on the type of anticoagulants, VKAs [6947 participants, OR = 1.26 (0.57,2.77); P = 0.57; I2 = 82%; Supplementary Figure 4A], DOACs [149564 participants, OR = 1.12 (0.58, 2.15); P = 0.74; I2 = 88%; Supplementary Figure 4B], and any anticoagulant use [36854 participants, OR = 1.07 (0.72, 1.58); P = 0.75; I2 = 89%; Supplementary Figure 4C] all reported non-significant association with severe COVID-19 disease. Similarly, prehospital anticoagulation was not significantly associated with COVID-19 disease severity in the adjusted analysis [12 studies[29,30,39,41,43,45,50,51,59,70-72]; aOR = 0.96 (0.72, 1.26); P = 0.76; I2 = 80%; Figure 3C].

Multivariate meta-regression model for mortality outcome

To account for variations in the correlation between mortality and prehospital anticoagulant use, a multivariate meta-regression was performed. The findings demonstrated that when considered collectively, the proportion of age, diabetes, female gender, hypertension, and pulmonary diseases was significant. These variables accounted for R2 = 90% of the difference in mortality between studies (Figure 4A).

Figure 4 Meta-regression analyses. A: Mortality meta-regression analysis; B: Severity meta-regression analysis.

Multivariate meta-regression model for severity outcome

Multivariate meta-regression was employed to take into consideration variations in the correlation between COVID-19 severity and prehospital anticoagulation. Together, age, female gender, and the proportion of hypertension, pulmonary disease, and diabetes were found to be significant covariates. Figure 4B demonstrates that these factors, all together, explained R2 = 100% for heterogeneity in severity among the included studies.

DISCUSSION

Our analysis offered a thorough examination of the risk of thromboembolic events, mortality, and severity of COVID-19 disease when anticoagulant medication was used prior to hospitalization. The meta-analysis identified no significant association between prehospital anticoagulation and decreased thromboembolic events risk and reduced COVID-19 disease severity. Though the unadjusted analysis exhibited a rise in mortality risk of COVID-19 patients with prior anticoagulation, adjusting the estimates revealed no significant difference in the odds of thromboembolic events, mortality, and severity between COVID-19 infected patients on prehospital anticoagulation and those without antecedent anticoagulation treatment.

Literature review and analysis of existing research

VTE: Coagulopathy and thromboembolic events are described as independent poor prognostic indicators in COVID-19[58,75]. Hospitalized COVID-19 patients tend to have a higher incidence of VTE than individuals with other illnesses[76], yet the exact mechanism of hypercoagulability remains unclear. COVID-19 infection can induce hyperinflammation[77], leading to endothelial dysfunction[78-80], platelet activation, blood stasis[58], and microvascular inflammation[81], all of which can influence consequent respiratory distress and other organ dysfunctioning[78-80]. This acute inflammatory state also increases the arterial and venous TE risk[61].

While ample evidence supports anticoagulation benefits during hospitalization[82-84], the role of prehospital anticoagulation before COVID-19 diagnosis, particularly in thromboembolic event incidence, lacks sufficient data. Despite anticoagulation, people on long-term oral anticoagulation therapy that started prior to COVID-19 infection may be more prone to thrombosis because of the existing SARS-CoV-2 infection[45]. Initial research suggests potential negative effects of VKAs on COVID-19[50]. SARS-CoV-2 infected individuals have reduced extra-hepatic vitamin K stores, which could be further decreased with VKAs[50]. However, studies have produced conflicting results regarding prehospital anticoagulation's impact on COVID-19 patients' thromboembolic risk, with some studies showing increased thromboembolic event risk[58]. In contrast, others observed benefits from prehospital anticoagulation in reducing COVID-related TE risk[29,50]. However, as shown in both unadjusted and adjusted analyses, our study did not find a significant reduction in thromboembolic events among COVID-19 patients receiving prehospital anticoagulation.

Mortality: Diverse study outcomes exist on chronic anticoagulation's impact on COVID-19 mortality. Tremblay et al[70] noted higher mortality among prehospital anticoagulated COVID-19 patients, yet non-significance emerged after age, sex, race, obesity, and Charlson Comorbidity Index adjustment. Rivera-Caravaca et al[58] reported higher all-cause mortality rates in prehospital DOAC-treated patients, remaining significant post-adjustment. Conversely, studies like Fumagillin et al’s[44] observed lower mortality rates in pre-COVID-19 anticoagulated patients[41,43,44,68]. Our research aligns with studies[41-51,69] and an earlier meta-analysis published by Kamel et al[85], revealing no substantial prehospital anticoagulation-associated mortality impact. Unlike Kamel et al[85], our study comprehensively explores pre-admission anticoagulation effects on VTE risk, severity of disease, and mortality in COVID-19.

Severity: Divergent results have been observed regarding the effect of anticoagulation on the severity of COVID-19[47,48,52,64,66,74]. Aslan et al[55] revealed significantly higher ICU admission, ventilation, oxygen therapy, and mortality rates with DOAC use. Yet, Corrochano et al’s[30] study found ICU admission reduction with prehospital anticoagulation after age, sex, and CCI adjustment. Similarly, Iaccarino et al[72] linked oral anticoagulants to ICU admission risk reduction. However, their cross-sectional design for hypothesis generation might influence outcomes[33].

Assessment of potential biases

The existence of selection bias and confounding bias is one possible explanation for inconsistent results among studies[29,30,49,55,58], as some studies include patients with cardiovascular or coagulation issues (poorer premorbid state). Certain studies neglect the effects of other medications during hospitalization[84]. Another reason can be the nature of the study, as observational and retrospective studies limit the causal inference[27-30,55], even though propensity score matching efforts[58], as propensity scoring is dependent on covariates and confounders are not included in the scoring, resulting in a potential bias. Small sample size also introduces bias[28,55]. The focus on hospitalized patients can hamper the generalizability of milder and asymptomatic COVID-19 cases. Similarly, heterogeneous sample sizes impact data collection and yield inconsistent results. Socio-demographics, like age and gender, may also influence drug effects on severity and mortality.

Possible mechanisms underlying the findings

A hypercoagulative state is promoted by COVID-19-induced coagulative abnormalities and alterations in prothrombotic factors, such as enhanced factor VIII, plasma fibrinogen, microparticles, and increased platelet activation[86-89]. This hypercoagulative state, known as COVID-19-associated coagulopathy (CAC), differs from acute disseminated intravascular coagulation (DIC) in presentation, involving thrombosis instead of bleeding[90]. Although D-dimer levels are elevated in both CAC and DIC, additional coagulation factors differentiate CAC (higher levels of Von Willebrand factor (vWF) antigen, Factor VIII activity, and fibrinogen) from DIC (lower levels of fibrinogen, reduced Factor VIII activity, and decreased VWF)[88-91].

Evidence suggests coagulation factor Xa's role in virus entry by cleaving SARS Spike proteins, which certain anticoagulants inhibit, potentially affecting viral fusion with ACE-2 receptors[10]. Ageno et al[28] used this concept to show DOACs' potentially higher antiviral efficacy over VKAs, though with limitations. Meanwhile, in our meta-analysis, DOAC-treated cases showed more severe disease progression than VKA-treated ones.

The underlying pathophysiology of endothelial damage by SARS-COV-2 is thought to be related to the renin-angiotensin-aldosterone system (RAAS). Virus-host cell binding via ACE-2 receptors raises disease severity risk. Thus, ACEI and ARBs (RAAS inhibitors) could heighten disease severity by increasing ACE2 receptor expression[16]. Anticoagulants, not affecting ACE2 receptors, might explain the non-significant enhancement in disease severity, as seen in our meta-analysis with no prehospital anticoagulation-COVID-19 severity correlation.

Clinical implications and future directions

Our study has significant clinical implications. Monitoring coagulation function in ICU patients using repeated platelet count, prothrombin time, and D-dimer measurements is vital. Elevated serum D-dimer predicts VTE and is a prognostic tool for COVID-19 risk stratification[92,93]. High D-dimer or rapid respiratory decline may indicate suspected VTE. Middeldorp et al[62] noted significantly higher D-dimer levels in ICU-admitted COVID-19-infected patients, regardless of chronic prehospital anticoagulation. Our analysis found that chronic anticoagulation does not significantly reduce the risk of new thromboembolic events in COVID-19 patients. This suggests that prior anticoagulation does not protect against COVID-19-related thromboembolic events. Due to the controversial effects of anticoagulant therapy on COVID-19 severity, further studies are needed.

Strengths and limitations

This meta-analysis's strengths include a sizable sample size dispersed across several nations and moderate to high-quality studies included according to the New-Castle Ottawa Scale. However, there are notable limitations. First, the retrospective nature of most included research limits the generalizability of the conclusions, highlighting the need for expansive prospective investigations. Second, while adjusted estimates were prioritized in the original analysis, selection bias and the confounding impact typical of observational research cannot be completely eliminated. Furthermore, inconsistency existed in the definition of severity among the included articles. Lastly, data gaps regarding prehospital anticoagulation specifics—duration, indication, type, and dosage—in some studies impeded comprehensive analysis.

CONCLUSION

The current meta-analysis concludes that prehospital anticoagulation does not significantly correlate with reduced COVID-19-related thromboembolic events, enhanced survival, or lowered disease severity risk. This aligns with recent guidelines advocating prophylactic anticoagulant use in COVID-19 patients, irrespective of VTE risk. To gain deeper insights and robust evidence, we suggest well-designed prospective studies and randomized trials investigating the impact of prior anticoagulant usage on thromboembolic risk, mortality, and disease severity in COVID-19 cases. Furthermore, a thorough exploration of the reasons behind the limited efficacy of chronic anticoagulants in severe infections is warranted. Future research should focus on determining personalized VTE risks for COVID-19 patients, uncovering underlying pathogenic pathways, and identifying optimal anticoagulant interventions for VTE prevention.

ACKNOWLEDGEMENTS

Data from this study was presented as an abstract format for the SCCM 2023 Critical Care Congress in San Francisco, California, United States.

Conflict-of-interest statement: Dr. Bansal has nothing to disclose.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Medical laboratory technology

Country of origin: United States

Peer-review report’s classification

Scientific Quality: Grade C

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade B

P-Reviewer: Adam CA, Romania S-Editor: Lin C L-Editor: A P-Editor: Zhang L
==== Refs
1 Zhu N Zhang D Wang W Li X Yang B Song J Zhao X Huang B Shi W Lu R Niu P Zhan F Ma X Wang D Xu W Wu G Gao GF Tan W China Novel Coronavirus Investigating and Research Team A Novel Coronavirus from Patients with Pneumonia in China, 2019 N Engl J Med 2020 382 727 733 31978945
2 Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry: Erratum Crit Care Med 2021 49 e562 33854027
3 Menon T Sharma R Earthineni G Iftikhar H Sondhi M Shams S Khurshid Ahmed N Khan H Rathore SS Singh R Association of Gastrointestinal System With Severity and Mortality of COVID-19: A Systematic Review and Meta-Analysis Cureus 2021 13 e13317 33738161
4 Menon T Sharma R Kataria S Sardar S Adhikari R Tousif S Khan H Rathore SS Singh R Ahmed Z The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis Cureus 2021 13 e13894 33880250
5 Rathore SS Rojas GA Sondhi M Pothuru S Pydi R Kancherla N Singh R Ahmed NK Shah J Tousif S Baloch UT Wen Q Myocarditis associated with Covid-19 disease: A systematic review of published case reports and case series Int J Clin Pract 2021 75 e14470 34235815
6 Shah K Bedi S Onyeaka H Singh R Chaudhari G The Role of Psychological First Aid to Support Public Mental Health in the COVID-19 Pandemic Cureus 2020 12 e8821 32742836
7 Shah K Mann S Singh R Bangar R Kulkarni R Impact of COVID-19 on the Mental Health of Children and Adolescents Cureus 2020 12 e10051 32999774
8 Sheraton M Deo N Kashyap R Surani S A Review of Neurological Complications of COVID-19 Cureus 2020 12 e8192 32455089
9 Singh R Kashyap R Hutton A Sharma M Surani S A Review of Cardiac Complications in Coronavirus Disease 2019 Cureus 2020 12 e8034 32528770
10 Singh R Rathore SS Khan H Bhurwal A Sheraton M Ghosh P Anand S Makadia J Ayesha F Mahapure KS Mehra I Tekin A Kashyap R Bansal V Mortality and Severity in COVID-19 Patients on ACEIs and ARBs-A Systematic Review, Meta-Analysis, and Meta-Regression Analysis Front Med (Lausanne) 2021 8 703661 35083229
11 Xie J Zu Y Alkhatib A Pham TT Gill F Jang A Radosta S Chaaya G Myers L Zifodya JS Bojanowski CM Marrouche NF Mauvais-Jarvis F Denson JL Metabolic Syndrome and COVID-19 Mortality Among Adult Black Patients in New Orleans Diabetes Care 2020 44 188 193 32843337
12 Denson JL Gillet AS Zu Y Brown M Pham T Yoshida Y Mauvais-Jarvis F Douglas IS Moore M Tea K Wetherbie A Stevens R Lefante J Shaffer JG Armaignac DL Belden KA Kaufman M Heavner SF Danesh VC Cheruku SR St Hill CA Boman K Deo N Bansal V Kumar VK Walkey AJ Kashyap R Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19 JAMA Netw Open 2021 4 e2140568 34935924
13 Bansal V Mahapure KS Bhurwal A Gupta I Hassanain S Makadia J Madas N Armaly P Singh R Mehra I O'Horo JC Kashyap R Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis Front Med (Lausanne) 2020 7 606429 33585508
14 Bansal V Mahapure KS Mehra I Bhurwal A Tekin A Singh R Gupta I Rathore SS Khan H Deshpande S Gulati S Armaly P Sheraton M Kashyap R Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis Front Med (Lausanne) 2021 8 624924 33898477
15 Singh R Shaik L Mehra I Kashyap R Surani S Novel and Controversial Therapies in COVID-19 Open Respir Med J 2020 14 79 86 33717367
16 Bikdeli B Madhavan MV Jimenez D Chuich T Dreyfus I Driggin E Nigoghossian C Ageno W Madjid M Guo Y Tang LV Hu Y Giri J Cushman M Quéré I Dimakakos EP Gibson CM Lippi G Favaloro EJ Fareed J Caprini JA Tafur AJ Burton JR Francese DP Wang EY Falanga A McLintock C Hunt BJ Spyropoulos AC Barnes GD Eikelboom JW Weinberg I Schulman S Carrier M Piazza G Beckman JA Steg PG Stone GW Rosenkranz S Goldhaber SZ Parikh SA Monreal M Krumholz HM Konstantinides SV Weitz JI Lip GYH Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review J Am Coll Cardiol 2020 75 2950 2973 32311448
17 Violi F Pastori D Cangemi R Pignatelli P Loffredo L Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge Thromb Haemost 2020 120 949 956 32349133
18 Jackson SP Darbousset R Schoenwaelder SM Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms Blood 2019 133 906 918 30642917
19 Paranjpe I Fuster V Lala A Russak AJ Glicksberg BS Levin MA Charney AW Narula J Fayad ZA Bagiella E Zhao S Nadkarni GN Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 J Am Coll Cardiol 2020 76 122 124 32387623
20 Page MJ McKenzie JE Bossuyt PM Boutron I Hoffmann TC Mulrow CD Shamseer L Tetzlaff JM Akl EA Brennan SE Chou R Glanville J Grimshaw JM Hróbjartsson A Lalu MM Li T Loder EW Mayo-Wilson E McDonald S McGuinness LA Stewart LA Thomas J Tricco AC Welch VA Whiting P Moher D The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 2021 372 n71 33782057
21 Chaudhari PB Banga A Writing strategies for improving the access of medical literature World J Exp Med 2023 13 50 58 37396881
22 WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection A minimal common outcome measure set for COVID-19 clinical research Lancet Infect Dis 2020 20 e192 e197 32539990
23 Cochrance Training Review Manager (RevMan). [cited 24 April 2022]. Available from: https://training.cochrane.org/online-learning/core-software/revman
24 Brüggemann P Rajguru K Comprehensive Meta-Analysis (CMA) 3.0: a software review J Market Anal 2022 10: 425 429
25 Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions. 2019
26 Wells GA Shea B O'Connell D Peterson J Welch V Tugwell P The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. [cited 24 April 2022]. Available from: https://cmr.cochrane.org/?CRGReportID=2972
27 Schünemann HJ Oxman AD Brozek J Glasziou P Jaeschke R Vist GE Williams JW Kunz R Craig J Montori VM Bossuyt P Guyatt GH Grading quality of evidence and strength of recommendations for diagnostic tests and strategies BMJ 2008 336 1106 18483053
28 Ageno W De Candia E Iacoviello L Di Castelnuovo A CORIST investigators Protective effect of oral anticoagulant drugs in atrial fibrillation patients admitted for COVID-19: Results from the CORIST study Thromb Res 2021 203 138 141 34020162
29 Arachchillage DJ Rajakaruna I Odho Z Crossette-Thambiah C Nicolson PLR Roberts LN Allan C Lewis S Riat R Mounter P Lynch C Langridge A Oakes R Aung N Drebes A Dutt T Raheja P Delaney A Essex S Lowe G Sutton D Lentaigne C Sayar Z Kilner M Everington T Shapiro S Alikhan R Szydlo R Makris M Laffan M Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK - a multicentre observational study Br J Haematol 2022 196 79 94 34500500
30 Corrochano M Acosta-Isaac R Mojal S Miqueleiz S Rodriguez D Quijada-Manuitt MÁ Fraga E Castillo-Ocaña M Amaro-Hosey K Albiol N Soria JM Antonijoan RM Souto JC Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19 J Thromb Thrombolysis 2022 53 96 102 34138399
31 Fröhlich GM Jeschke E Eichler U Thiele H Alhariri L Reinthaler M Kastrati A Leistner DM Skurk C Landmesser U Günster C Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany Clin Res Cardiol 2021 110 1041 1050 33416918
32 Gülcü O Aksakal E Aydemir S Doğan R Saraç İ Aydın SŞ Öztürk M Aksu U Kalkan K Tanboğa İH Association between previous anticoagulant use and mortality among hospitalized patients with COVID-19 J Thromb Thrombolysis 2022 53 88 95 34080103
33 Hanif A Khan S Mantri N Hanif S Saleh M Alla Y Chinta S Shrestha N Ji W Attwood K Adrish M Jain KR Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience Ann Hematol 2020 99 2323 2328 32808105
34 Harrison RF Forte K Buscher MG Jr Chess A Patel A Moylan T Mize CH Werdmann M Ferrigno R The Association of Preinfection Daily Oral Anticoagulation Use and All-Cause in Hospital Mortality From Novel Coronavirus 2019 at 21 Days: A Retrospective Cohort Study Crit Care Explor 2021 3 e0324 33521644
35 Hozayen SM Zychowski D Benson S Lutsey PL Haslbauer J Tzankov A Kaltenborn Z Usher M Shah S Tignanelli CJ Demmer RT Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients EClinicalMedicine 2021 41 101139 34585129
36 Li X Xu S Yu M Wang K Tao Y Zhou Y Shi J Zhou M Wu B Yang Z Zhang C Yue J Zhang Z Renz H Liu X Xie J Xie M Zhao J Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan J Allergy Clin Immunol 2020 146 110 118 32294485
37 Rieder M Gauchel N Kaier K Jakob C Borgmann S Classen AY Schneider J Eberwein L Lablans M Rüthrich M Dolff S Wille K Haselberger M Heuzeroth H Bode C von Zur Mühlen C Rieg S Duerschmied D Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities Clin Res Cardiol 2022 111 322 332 34546427
38 Rivera-Caravaca JM Núñez-Gil IJ Vivas D Viana-Llamas MC Uribarri A Becerra-Muñoz VM Trabattoni D Fernández Rozas I Feltes G López-Pais J El-Battrawy I Macaya C Fernandez-Ortiz A Estrada V Marín F HOPE COVID-19 Investigators Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19 Eur J Clin Invest 2021 51 e13436 33080051
39 Togano T Uemura Y Asai Y Hayakawa K Matsunaga N Terada M Ohtsu H Suzuki S Toyoda A Hara H Sato R Ishikane M Kinoshita-Iwamoto N Hangaishi A Ohmagari N The influence of pre-admission antiplatelet and anticoagulation therapy on the illness severity in hospitalized patients with COVID-19 in Japan J Infect Chemother 2021 27 1498 1503 34340930
40 Buenen AG Sinkeldam M Maas ML Verdonschot M Wever PC Prior use of anticoagulation is associated with a better survival in COVID-19 J Thromb Thrombolysis 2021 52 1207 1211 34061283
41 Chocron R Galand V Cellier J Gendron N Pommier T Bory O Khider L Trimaille A Goudot G Weizman O Alsac JM Geneste L Schmeltz A Panagides V Philippe A Marsou W Ben Abdallah I Deney A El Batti S Attou S Juvin P Delmotte T Messas E Pezel T Planquette B Duceau B Gaussem P Sutter W Sanchez O Waldman V Diehl JL Mirault T Bonnet G Cohen A Smadja DM Critical COVID‐19 France Investigators Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID-19: Insight From a French Multicenter Cohort Study J Am Heart Assoc 2021 10 e018624 33550816
42 Covino M De Matteis G Della Polla D Burzo ML Pascale MM Santoro M De Cristofaro R Gasbarrini A De Candia E Franceschi F Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients? Aging Clin Exp Res 2021 33 2335 2343 34216379
43 Denas G Gennaro N Ferroni E Fedeli U Lorenzoni G Gregori D Iliceto S Pengo V Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study Int J Cardiol 2021 329 266 269 33309764
44 Fumagalli S Trevisan C Del Signore S Pelagalli G Volpato S Gareri P Mossello E Malara A Monzani F Coin A Bellelli G Zia G Antonelli Incalzi R GeroCovid Working Group COVID-19 and Atrial Fibrillation in Older Patients: Does Oral Anticoagulant Therapy Provide a Survival Benefit?-An Insight from the GeroCovid Registry Thromb Haemost 2022 122 105 112 33962480
45 Ho G Dusendang JR Schmittdiel J Kavecansky J Tavakoli J Pai A Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients J Thromb Thrombolysis 2021 52 476 481 33527183
46 Olcott F Hunt C Chan T Williams G Pre-admission anti-coagulation does not improve all-cause mortality in geriatric COVID-19 patients Clin Med (Lond) 2021 21 7 8 34078675
47 Parker K Hamilton P Hanumapura P Castelino L Murphy M Challiner R Thachil J Ebah L Chronic anticoagulation is not associated with a reduced risk of acute kidney injury in hospitalised Covid-19 patients BMC Nephrol 2021 22 224 34134645
48 Russo V Bottino R D'Andrea A Silverio A Di Maio M Golino P Nigro G Valsecchi O Attena E Canonico ME Galasso G Parodi G Scudiero F Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 Patients Cardiovasc Drugs Ther 2022 36 705 712 33988835
49 Sivaloganathan H Ladikou EE Chevassut T COVID-19 mortality in patients on anticoagulants and antiplatelet agents Br J Haematol 2020 190 e192 e195 32584423
50 Spiegelenberg JP van Gelder MMHJ Maas ML Hovens MMC Esselink A Dofferhoff ASM Janssen R van de Maat J Janssen N Blaauw M Hassing RJ van Apeldoorn M Kerckhoffs A Veerman K Hoogerwerf J Kramers C Leentjens J Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: A propensity score-matched cohort study Br J Clin Pharmacol 2021 87 4839 4847 33899226
51 van Haaps TF Collard D van Osch FHM Middeldorp S Coppens M de Kruif MD Vlot EA Douma RA Ten Cate H Juffermans NP Gritters N Vlaar AP Reidinga AC Heuvelmans MA Oudkerk M Büller HR van den Bergh JPW Maas A Ten Wolde M Simsek S Corona Research Fund Amsterdam UMC, Beudel M, van Es N Dutch COVID & Thrombosis Coalition Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study Thromb Res 2021 208 35 38 34688100
52 Zheng Z Peng F Xu B Zhao J Liu H Peng J Li Q Jiang C Zhou Y Liu S Ye C Zhang P Xing Y Guo H Tang W Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis J Infect 2020 81 e16 e25
53 Brouns SH Brüggemann R Linkens AEMJH Magdelijns FJ Joosten H Heijnen R Ten Cate-Hoek AJ Schols JMGA Ten Cate H Spaetgens B Mortality and the Use of Antithrombotic Therapies Among Nursing Home Residents with COVID-19 J Am Geriatr Soc 2020 68 1647 1652 32633418
54 Fauvel C Weizman O Trimaille A Mika D Pommier T Pace N Douair A Barbin E Fraix A Bouchot O Benmansour O Godeau G Mecheri Y Lebourdon R Yvorel C Massin M Leblon T Chabbi C Cugney E Benabou L Aubry M Chan C Boufoula I Barnaud C Bothorel L Duceau B Sutter W Waldmann V Bonnet G Cohen A Pezel T Critical Covid-19 France Investigators Pulmonary embolism in COVID-19 patients: a French multicentre cohort study Eur Heart J 2020 41 3058 3068 32656565
55 Aslan B Akyüz A Işık F Çap M İnci Ü Kaya İ Karahan MZ Aktan A Bilge Ö Özbek M Altıntaş B Boyraz B The effect of chronic DOAC treatment on clinical outcomes of hospitalized patients with COVID-19 Int J Clin Pract 2021 75 e14467 34107130
56 Ruzhentsova TA Khavkina DA Chukhliaev PV Garbuzov AA Ploskireva AA [Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients] Vopr Virusol 2021 66 40 46 33683064
57 Rossi R Coppi F Talarico M Boriani G Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era Eur J Intern Med 2020 77 158 160 32564905
58 Rivera-Caravaca JM Buckley BJR Harrison SL Fazio-Eynullayeva E Underhill P Marín F Lip GYH Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes Thromb Res 2021 205 1 7 34218058
59 Flam B Wintzell V Ludvigsson JF Mårtensson J Pasternak B Direct oral anticoagulant use and risk of severe COVID-19 J Intern Med 2021 289 411 419 33258156
60 Ménager P Brière O Gautier J Riou J Sacco G Brangier A Annweiler C Geria-Covid Study Group OBOT Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study Nutrients 2020 13
61 Klok FA Kruip MJHA van der Meer NJM Arbous MS Gommers D Kant KM Kaptein FHJ van Paassen J Stals MAM Huisman MV Endeman H Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis Thromb Res 2020 191 148 150 32381264
62 Middeldorp S Coppens M van Haaps TF Foppen M Vlaar AP Müller MCA Bouman CCS Beenen LFM Kootte RS Heijmans J Smits LP Bonta PI van Es N Incidence of venous thromboembolism in hospitalized patients with COVID-19 J Thromb Haemost 2020 18 1995 2002 32369666
63 Natali KM Chan KH Atallah L Nagarakanti S Slim J 552. Could Anticoagulant Use Prior to Infection with COVID-19 Decrease Mortality? Open Forum Infect Di 2020 7 S342 S342
64 Reilev M Kristensen KB Pottegård A Lund LC Hallas J Ernst MT Christiansen CF Sørensen HT Johansen NB Brun NC Voldstedlund M Støvring H Thomsen MK Christensen S Gubbels S Krause TG Mølbak K Thomsen RW Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort Int J Epidemiol 2020 49 1468 1481 32887982
65 Wargny M Potier L Gourdy P Pichelin M Amadou C Benhamou PY Bonnet JB Bordier L Bourron O Chaumeil C Chevalier N Darmon P Delenne B Demarsy D Dumas M Dupuy O Flaus-Furmaniuk A Gautier JF Guedj AM Jeandidier N Larger E Le Berre JP Lungo M Montanier N Moulin P Plat F Rigalleau V Robert R Seret-Bégué D Sérusclat P Smati S Thébaut JF Tramunt B Vatier C Velayoudom FL Vergès B Winiszewski P Zabulon A Gourraud PA Roussel R Cariou B Hadjadj S CORONADO investigators Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study Diabetologia 2021 64 778 794 33599800
66 Philipose Z Smati N Wong CSJ Aspey K Mendall MA Obesity, old age and frailty are the true risk factors for COVID-19 mortality and not chronic disease or ethnicity in Croydon. 2020 Preprint. Available from: https://www.medrxiv.org/content/10.1101/2020.08.12.20156257v3
67 Rodríguez-Molinero A Gálvez-Barrón C Miñarro A Macho O López GF Robles MT Dapena MD Martínez S Milà Ràfols N Monaco EE Hidalgo García A COVID-19 Research Group of CSAPG Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients PLoS One 2020 15 e0239571 33057443
68 Boari GEM Chiarini G Bonetti S Malerba P Bianco G Faustini C Braglia-Orlandini F Turini D Guarinoni V Saottini M Viola S Ferrari-Toninelli G Pasini G Mascadri C Bonzi B Desenzani P Tusi C Zanotti E Nardin M Rizzoni D Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study Biosci Rep 2020 40
69 Tehrani S Killander A Åstrand P Jakobsson J Gille-Johnson P Risk factors for death in adult COVID-19 patients: Frailty predicts fatal outcome in older patients Int J Infect Dis 2021 102 415 421 33130213
70 Tremblay D van Gerwen M Alsen M Thibaud S Kessler A Venugopal S Makki I Qin Q Dharmapuri S Jun T Bhalla S Berwick S Feld J Mascarenhas J Troy K Cromwell C Dunn A Oh WK Naymagon L Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study Blood 2020 136 144 147 32462179
71 Bauer AZ Gore R Sama SR Rosiello R Garber L Sundaresan D McDonald A Arruda P Kriebel D Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study J Clin Hypertens (Greenwich) 2021 23 21 27 33220171
72 Iaccarino G Grassi G Borghi C Grassi D Mancusi C Muiesan ML Salvetti M Volpe M Ferri C Preexisting Oral Anticoagulant Therapy Ameliorates Prognosis in Hospitalized COVID-19 Patients Front Cardiovasc Med 2021 8 633878 34055928
73 Lodigiani C Iapichino G Carenzo L Cecconi M Ferrazzi P Sebastian T Kucher N Studt JD Sacco C Bertuzzi A Sandri MT Barco S Humanitas COVID-19 Task Force Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy Thromb Res 2020 191 9 14 32353746
74 Schiavone M Gasperetti A Mancone M Curnis A Mascioli G Mitacchione G Busana M Sabato F Gobbi C Antinori S Galli M Forleo GB Oral anticoagulation and clinical outcomes in COVID-19: An Italian multicenter experience Int J Cardiol 2021 323 276 280 32911000
75 Cui S Chen S Li X Liu S Wang F Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia J Thromb Haemost 2020 18 1421 1424 32271988
76 Zhang C Shen L Le KJ Pan MM Kong LC Gu ZC Xu H Zhang Z Ge WH Lin HW Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis Front Cardiovasc Med 2020 7 151 32850990
77 Costela-Ruiz VJ Illescas-Montes R Puerta-Puerta JM Ruiz C Melguizo-Rodríguez L SARS-CoV-2 infection: The role of cytokines in COVID-19 disease Cytokine Growth Factor Rev 2020 54 62 75 32513566
78 Libby P Lüscher T COVID-19 is, in the end, an endothelial disease Eur Heart J 2020 41 3038 3044 32882706
79 Lowenstein CJ Solomon SD Severe COVID-19 Is a Microvascular Disease Circulation 2020 142 1609 1611 32877231
80 Teuwen LA Geldhof V Pasut A Carmeliet P Author Correction: COVID-19: the vasculature unleashed Nat Rev Immunol 2020 20 448
81 Talaei F Banga A Pursell A Gage A Pallipamu N Seri AR Adhikari R Kashyap R Surani S New-onset atrial fibrillation among COVID-19 patients: A narrative review World J Crit Care Med 2023 12 236 247 38188450
82 Cuker A Tseng EK Nieuwlaat R Angchaisuksiri P Blair C Dane K Davila J DeSancho MT Diuguid D Griffin DO Kahn SR Klok FA Lee AI Neumann I Pai A Pai M Righini M Sanfilippo KM Siegal D Skara M Touri K Akl EA Bou Akl I Boulos M Brignardello-Petersen R Charide R Chan M Dearness K Darzi AJ Kolb P Colunga-Lozano LE Mansour R Morgano GP Morsi RZ Noori A Piggott T Qiu Y Roldan Y Schünemann F Stevens A Solo K Ventresca M Wiercioch W Mustafa RA Schünemann HJ American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv 2021 5 872 888 33560401
83 Rentsch CT Beckman JA Tomlinson L Gellad WF Alcorn C Kidwai-Khan F Skanderson M Brittain E King JT Jr Ho YL Eden S Kundu S Lann MF Greevy RA Jr Ho PM Heidenreich PA Jacobson DA Douglas IJ Tate JP Evans SJW Atkins D Justice AC Freiberg MS Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study BMJ 2021 372 n311 33574135
84 Tang N Bai H Chen X Gong J Li D Sun Z Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy J Thromb Haemost 2020 18 1094 1099 32220112
85 Kamel AM Sobhy M Magdy N Sabry N Farid S Anticoagulation outcomes in hospitalized Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies Rev Med Virol 2021 31 e2180 33022834
86 Hottz ED Azevedo-Quintanilha IG Palhinha L Teixeira L Barreto EA Pão CRR Righy C Franco S Souza TML Kurtz P Bozza FA Bozza PT Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 Blood 2020 136 1330 1341 32678428
87 Maier CL Truong AD Auld SC Polly DM Tanksley CL Duncan A COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? Lancet 2020 395 1758 1759 32464112
88 Panigada M Bottino N Tagliabue P Grasselli G Novembrino C Chantarangkul V Pesenti A Peyvandi F Tripodi A Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis J Thromb Haemost 2020 18 1738 1742 32302438
89 Ranucci M Ballotta A Di Dedda U Baryshnikova E Dei Poli M Resta M Falco M Albano G Menicanti L The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome J Thromb Haemost 2020 18 1747 1751 32302448
90 Connors JM Levy JH Thromboinflammation and the hypercoagulability of COVID-19 J Thromb Haemost 2020 18 1559 1561 32302453
91 Fogarty H Townsend L Ni Cheallaigh C Bergin C Martin-Loeches I Browne P Bacon CL Gaule R Gillett A Byrne M Ryan K O'Connell N O'Sullivan JM Conlon N O'Donnell JS COVID19 coagulopathy in Caucasian patients Br J Haematol 2020 189 1044 1049 32330308
92 Kollias A Kyriakoulis KG Dimakakos E Poulakou G Stergiou GS Syrigos K Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action Br J Haematol 2020 189 846 847 32304577
93 Thachil J Tang N Gando S Falanga A Cattaneo M Levi M Clark C Iba T ISTH interim guidance on recognition and management of coagulopathy in COVID-19 J Thromb Haemost 2020 18 1023 1026 32338827
